Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …

Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …

Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in
various cellular processes, including cell migration, morphological differentiation, cell …

MET has been considered as a promising drug target for the treatment of MET-dependent
diseases, particularly non-small cell lung cancer (NSCLC). Small molecule MET inhibitors …

Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical
trials, both as a single agent and in combination. Here, we describe the preclinical data of …

Introduction ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic
efficacy of crizotinib in this subset has been shown in early phase trials in the United States …

Fusions involving the oncogenic gene RET have been observed in thyroid and lung
cancers. Here we report RET gene alterations, including amplification, missense mutations …

Treatment of advanced non-small cell lung cancer (NSCLC) has radically improved in the
last years due to development and clinical approval of highly effective agents including …

Non-small cell lung cancer (NSCLC) patients with sensitizing oncogenic driver mutations
benefit from targeted therapies. Tyrosine kinase inhibitors are highly effective against classic …